Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Covidien Provides Sales Targets for Pharma Spinoff

By Pharmaceutical Processing | May 6, 2013

NEW YORK (AP) — Covidien PLC on Friday provided further details on its business following the planned spinoff of Mallinckrodt, its pharmaceuticals unit.

The Irish company expects to complete the spinoff after the close of trading on June 28. It said revenue from its remaining businesses, which sell medical devices and supplies, will grow by 4 or 5 percent in the current fiscal year. Covidien said revenue for Mallinckrodt is expected to grow between 7 and 11 percent. Those estimates both assume foreign currency exchange rates will hold steady for the rest of the year.

The company’s fiscal year ends Sept. 27.

Covidien expects medical device revenue to grow by 4 to 6 percent and medical supply revenue to rise by 1 or 2 percent. That’s down slightly from its earlier estimates because of unfavorable changes in currency exchange rates.

The company said revenue from Mallinckrodt’s specialty drug business will grow by 21 to 25 percent with medical imaging revenue down by 3 to 7 percent. It is forecasting at least $125 million in sales of generic extended-release Ritalin, and at least $100 million in revenue from chronic pain drug Exalgo.

Mallinckrodt expects to report around $130 million in annual corporate, governance, and international infrastructure costs that had been handled by Covidien. That’s an increase of about $40 million from the previous fiscal year. That estimate does not include any one-time costs or potential savings from restructuring or other changes.

Shares of Covidien rose 12 cents to close at $64.35.

 

Related Articles Read More >

Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE